Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/44609
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Budde E. | - |
dc.contributor.author | Gopal A.K. | - |
dc.contributor.author | Kim W.S. | - |
dc.contributor.author | Flinn I.W. | - |
dc.contributor.author | Cheah C.Y.Y. | - |
dc.contributor.author | Nastoupil L. | - |
dc.contributor.author | Matasar M.J. | - |
dc.contributor.author | Diefenbach C.S. | - |
dc.contributor.author | Gregory G.P. | - |
dc.contributor.author | Qazi I. | - |
dc.contributor.author | Pang C.-F. | - |
dc.contributor.author | Leabman M. | - |
dc.contributor.author | Hernandez G. | - |
dc.contributor.author | Sison I. | - |
dc.contributor.author | Keyt B.A. | - |
dc.contributor.author | Chen D. | - |
dc.contributor.author | Armand P. | - |
dc.date.accessioned | 2022-02-09T05:39:26Z | - |
dc.date.available | 2022-02-09T05:39:26Z | - |
dc.date.copyright | 2021 | - |
dc.date.issued | 2022-01-05 | en |
dc.identifier.citation | Blood. Conference: 63rd ASH Annual Meeting. Atlanta United States. 138(Supplement 1) (pp 132), 2021. Date of Publication: 23 Nov 2021. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/44609 | - |
dc.description.abstract | Introduction: IGM-2323 is the first engineered high-affinity, high-avidity bispecific IgM monoclonal antibody TCE to be tested in the clinic. It has 10 binding domains for CD20 and a single binding domain for CD3 and is designed to bind irreversibly to CD20-high and low-expressing cells with more physiologic stimulation to T cells, which may mitigate cytokine release syndrome (CRS)-related toxicity and broaden the therapeutic window. IGM-2323 may act by multiple mechanisms: T-cell dependent cytotoxicity, complement dependent cytotoxicity, and enhanced immune modulation via IFNgamma-dominant cytokine stimulation. This phase 1 study is exploring the safety and activity of IGM-2323 using a dose titration schedule intended to optimize repeatable immune stimulation while minimizing toxicity. Method(s): This first-in-human Phase 1 study is a global, multicenter, open-label, dose escalation evaluating safety, tolerability, PK, and preliminary efficacy (NCT04082936). Adults with relapsed or refractory CD20 + B-cell NHL with >= 2 prior systemic therapies, adequate organ function, and ECOG 0-1 are eligible. IGM-2323 is given IV on Days 1, 8, and 15 of 21-day cycles until disease progression or unacceptable toxicity. Treatment can continue beyond progression if the patient (pt) has benefitted from treatment and intra-patient dose escalation is allowed. This study also utilizes a dose titration scheme where a starting dose is given on Day 1, then higher subsequent doses...Copyright © 2021 American Society of Hematology | - |
dc.publisher | Elsevier B.V. | - |
dc.subject.mesh | *advanced cancer | - |
dc.subject.mesh | B cell lymphoma | - |
dc.subject.mesh | *cancer patient | - |
dc.subject.mesh | cancer recurrence | - |
dc.subject.mesh | drug megadose | - |
dc.subject.mesh | drug safety | - |
dc.subject.mesh | drug therapy | - |
dc.subject.mesh | *drug tolerability | - |
dc.subject.mesh | immunostimulation | - |
dc.subject.mesh | phase 1 clinical trial | - |
dc.subject.mesh | *plasmacytoma | - |
dc.subject.mesh | systemic therapy | - |
dc.subject.mesh | *T lymphocyte | - |
dc.subject.mesh | titrimetry | - |
dc.subject.mesh | *CD20 antibody | - |
dc.subject.mesh | *CD3 antibody | - |
dc.subject.mesh | endogenous compound | - |
dc.subject.mesh | *immunoglobulin M | - |
dc.title | A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. | - |
dc.type | Conference Abstract | - |
dc.description.conferencename | 63rd ASH Annual Meeting | - |
dc.description.conferencelocation | Atlanta, United States | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1182/blood-2021-153355 | - |
local.date.conferencestart | 20211-2-11 | - |
dc.identifier.institution | (Gregory) School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia | en |
dc.identifier.institution | (Budde) T Cell Therapeutics Research Laboratory, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States | en |
dc.identifier.institution | (Gopal) Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, University of Washington, Seattle, WA, United States | en |
dc.identifier.institution | (Kim) Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea | en |
dc.identifier.institution | (Flinn) Sarah Cannon Research Institute, Nashville, TN, United States | en |
dc.identifier.institution | (Cheah) Department of Haematology, NW Cancer Centre, Perth, Australia | en |
dc.identifier.institution | (Nastoupil) Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States | en |
dc.identifier.institution | (Matasar) Memorial Sloan Kettering Cancer Center, New York, NY, United States | en |
dc.identifier.institution | (Diefenbach) Perlmutter Cancer Center at NYU Langone Health, New York, NY, United States | en |
dc.identifier.institution | (Qazi, Leabman, Hernandez, Sison, Keyt, Chen) IGM Biosciences, Mountain View, CA, United States | en |
dc.identifier.institution | (Pang) Phi Consulting Group, Bellevue, WA, United States | en |
dc.identifier.institution | (Armand) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States | en |
local.date.conferenceend | 20211-2-14 | - |
dc.subect.keywords | adult | - |
dc.subect.keywords | conference abstract | - |
dc.subect.keywords | controlled study | - |
dc.subect.keywords | human | - |
dc.subect.keywords | multicenter study | - |
dc.identifier.affiliationext | (Budde) T Cell Therapeutics Research Laboratory, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States | - |
dc.identifier.affiliationext | (Gopal) Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, University of Washington, Seattle, WA, United States | - |
dc.identifier.affiliationext | (Kim) Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea | - |
dc.identifier.affiliationext | (Flinn) Sarah Cannon Research Institute, Nashville, TN, United States | - |
dc.identifier.affiliationext | (Cheah) Department of Haematology, NW Cancer Centre, Perth, Australia | - |
dc.identifier.affiliationext | (Nastoupil) Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States | - |
dc.identifier.affiliationext | (Matasar) Memorial Sloan Kettering Cancer Center, New York, NY, United States | - |
dc.identifier.affiliationext | (Diefenbach) Perlmutter Cancer Center at NYU Langone Health, New York, NY, United States | - |
dc.identifier.affiliationext | (Qazi, Leabman, Hernandez, Sison, Keyt, Chen) IGM Biosciences, Mountain View, CA, United States | - |
dc.identifier.affiliationext | (Pang) Phi Consulting Group, Bellevue, WA, United States | - |
dc.identifier.affiliationext | (Armand) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States | - |
dc.identifier.affiliationmh | (Gregory) School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Conference Abstract | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Appears in Collections: | Conferences |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.